BlueRock Therapeutics LP – Trademark Portfolio
Entity Type: 13
BlueRock Therapeutics LP holds 3 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 42 (Computer & Scientific) — 3 filings in this category. The portfolio also extends into Class 44 (Medical Services) across 3 Nice Classification classes. Currently, 1 trademark is registered and 2 are pending. Notable registered marks include BLUEROCK. The owner is based in Cambridge, MA.
238 Main Street, 3rd Floor
Cambridge, MA 02142
Showing of trademarks Trademarks
Trademark Classifications
BlueRock Therapeutics LP's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific and technological services; industrial analysis and research services
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does BlueRock Therapeutics LP have?
BlueRock Therapeutics LP has 3 U.S. trademarks filed with the USPTO. Of these, 1 registered, 2 pending.
What trademark classes does BlueRock Therapeutics LP file in?
BlueRock Therapeutics LP files trademarks across 3 Nice Classification classes. The most active classes are Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 5 (Pharmaceuticals). Class 42 covers scientific and technological services; industrial analysis and research services.
What are BlueRock Therapeutics LP's most well-known trademarks?
BlueRock Therapeutics LP's registered trademark portfolio includes well-known marks such as BLUEROCK. These are among 1 currently registered trademark in the portfolio.
What is BlueRock Therapeutics LP's trademark registration success rate?
BlueRock Therapeutics LP has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 2 applications are pending review.